logo-loader
viewOncimmune

Oncimmune boost as study shows its blood test could play a 'highly cost-effective' role in lung cancer surveillance

Academics looked at the deployment of the EarlyCDT Lung test in combination with computed tomography

Oncimmune -

Oncimmune Holdings PLC (LON:ONC) said an approach to managing lung cancer that uses the EarlyCDT Lung test pioneered by the group has been deemed “highly cost-effective” by healthcare economists.

The study, led by academics from Leeds University, assessed the treatment of people with indeterminate pulmonary nodules (IPNs).

It looked at the deployment of the £70 Oncimmune blood test in combination with computed tomography and compared it with using the CT scans on their own.

Not only did the approach have a “positive impact on the outcomes of those patients observed”, but it also provided a cost-effective method of managing patients.

Researchers calculated the incremental cost-effectiveness ratio to be £2,417, substantially below the accepted £20,000 per quality-adjusted life-year threshold set by the National Institute for Health and Care Excellence (NICE).

Oncimmune chief executive Adam Hill lauded the work of the Leeds University Academic Unit of Health Economics, which was supported by the NIHR Leeds In Vitro Diagnostics Co-operative, adding he was “very pleased” with the results.

“This study has enabled the generation of further data for the EarlyCDT Lung blood test that supports its adoption in ongoing discussions with healthcare providers across the UK," he added in a statement.

The research was published PLOS ONE, a site for peer-reviewed academic research.

Quick facts: Oncimmune

Price: 149.5 GBX

AIM:ONC
Market: AIM
Market Cap: £94.99 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Oncimmune CEO says they're seeing 'significant interest' in its EarlyCDT...

Oncimmune Holdings PLC's (LON:ONC) Adam Hill tells Proactive the next 18 months are expected to create substantial revenues within the EarlyCDT lung cancer test business while the pipeline of contracts within the ImmunoINSIGHTS services business is building. In a trading update covering the...

on 5/6/20

2 min read